Terkko Navigator / Cancer Letters

Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer

Beta2 glycoprotein I-derived therapeutic peptides induce sFlt-1 secretion to reduce melanoma vascularity and growth

Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect

A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity

Extracellular RNA: Emerging roles in cancer cell communication and biomarkers

Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer

The microRNA-424/503 cluster: A master regulator of tumorigenesis and tumor progression with paradoxical roles in cancer

The epigenetic roles of DNA N6-Methyladenine (6mA) modification in eukaryotes

ADAM28: Another ambivalent protease in cancer

Corrigendum to “FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer” [Canc. Lett. 397 (2017) 83–93]

TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends

Hypoxia-driven intratumor heterogeneity and immune evasion

CAR T-cell therapy for triple-negative breast cancer: Where we are

Exosomes in head and neck cancer: Roles, mechanisms and applications

Comment on ‘Clinical significance and inflammatory landscapes of a novel recurrence associated immune signature in early-stage lung adenocarcinoma’

Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity

UDP-glucose 6-dehydrogenase knockout impairs migration and decreases in vivo metastatic ability of breast cancer cells

Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis

Response to comment on ‘clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma’

Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation

miR-204/COX5A axis contributes to invasion and chemotherapy resistance in estrogen receptor-positive breast cancers

Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer

Neutrophils: Accomplices in metastasis

Corrigendum to“PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responsesˮ [Canc. Lett. 476 (2020) 170–182]

Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model

Silencing of miR490–3p by H. pylori activates DARPP-32 and induces resistance to gefitinib

Differential mutation spectrum and immune landscape in African Americans versus whites: A possible determinant to health disparity in head and neck cancer

Platelet factor 4 regulates T cell effector functions in malignant pleural effusions

Intestinal estrogen receptor beta suppresses colon inflammation and tumorigenesis in both sexes

Non-coding RNAs in gastric cancer

Sterol synthesis pathway inhibition as a target for cancer treatment

Recent advances in strategies for overcoming hypoxia in photodynamic therapy of cancer

UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation

Corrigendum to “NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma” [Canc. Lett. 476 (2020) 48–56]

Corrigendum to “Prevention of epithelial to mesenchymal transition in colorectal carcinoma by regulation of the E-cadherin-β-catenin-vinculin axis” [Cancer Lett. 452 (2019) 254–263]

Non-coding RNAs, metabolic stress and adaptive mechanisms in cancer

Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer

A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells

Cancer-associated fibroblasts-derived exosomal miR-17-5p promotes colorectal cancer aggressive phenotype by initiating a RUNX3/MYC/TGF-β1 positive feedback loop

Bacteria-derived minicells for cancer therapy

Remodeling of the ARID1A tumor suppressor

Three dimensional engineered models to study hypoxia biology in breast cancer

Hypoxia-responsive nanoparticles for tumor-targeted drug delivery

Pancreatic stellate cells derived exosomal miR-5703 promotes pancreatic cancer by downregulating CMTM4 and activating PI3K/Akt pathway

Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells

Direct targeting of HSP90 with daurisoline destabilizes β-catenin to suppress lung cancer tumorigenesis

Laser Interstitial Thermal Therapy in the treatment of brain metastases and radiation necrosis

The two faces of giant cell tumor of bone

Beyond glycolysis: Hypoxia signaling as a master regulator of alternative metabolic pathways and the implications in clear cell renal cell carcinoma